Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HILSNASDAQ:MRNSOTCMKTS:NRIFFOTCMKTS:SOAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHILSHillstream BioPharma$1.86+2.2%$1.50$0.19▼$2.65$32.74M3.081.39 million shs12,482 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.84 million shs260 shsNRIFFNuvo Pharmaceuticals$0.00$0.30▼$0.87$8.52M1.577,337 shs3,000 shsSOANAngioSoma$0.00$0.00▼$0.09$32.57M-0.466.74 million shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHILSHillstream BioPharma0.00%+3.19%+18.01%+58.30%-43.81%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-54.62%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SOANAngioSoma0.00%0.00%0.00%0.00%-75.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals2.3399 of 5 stars3.20.00.04.20.61.70.6NRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHILSHillstream BioPharma 0.00N/AN/AN/AMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideNRIFFNuvo Pharmaceuticals 0.00N/AN/AN/ASOANAngioSoma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77NRIFFNuvo Pharmaceuticals$52.41M0.00N/A0.82$1.59 per share0.00SOANAngioSomaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/AMRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)NRIFFNuvo Pharmaceuticals$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/ASOANAngioSoma-$540KN/A0.00N/AN/AN/AN/A-1,245.34%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHILSHillstream BioPharmaN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHILSHillstream BioPharmaN/A3.013.01MRNSMarinus PharmaceuticalsN/A1.661.47NRIFFNuvo Pharmaceuticals5.272.672.11SOANAngioSomaN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHILSHillstream BioPharma13.36%MRNSMarinus Pharmaceuticals98.80%NRIFFNuvo PharmaceuticalsN/ASOANAngioSoma0.02%Insider OwnershipCompanyInsider OwnershipHILSHillstream BioPharma30.24%MRNSMarinus Pharmaceuticals5.46%NRIFFNuvo PharmaceuticalsN/ASOANAngioSomaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableNRIFFNuvo Pharmaceuticals9911.40 millionN/ANot OptionableSOANAngioSomaN/A476.83 millionN/ANot OptionableNRIFF, SOAN, HILS, and MRNS HeadlinesRecent News About These CompaniesWatch: Unhygienic Making Process Of Soan Papdi Goes Viral, Leaves Internet DisgustedNovember 7, 2024 | food.ndtv.comFNational Security Adviser and Joint Chiefs Chair at U.S. Global Leadership ForumSeptember 19, 2024 | c-span.orgCC-SPAN TV ScheduleAugust 21, 2024 | c-span.orgCC-SPAN Radio ScheduleJuly 31, 2024 | c-span.orgCC-SPAN 2 TV ScheduleJuly 29, 2024 | c-span.orgCQ&A with Riley GainesJuly 19, 2024 | c-span.orgCSenate SessionApril 28, 2024 | c-span.orgCMartin SoanApril 22, 2024 | chortle.co.ukCDeath Clock / Life Span ClockApril 17, 2024 | medindia.netMWisconsin for KennedyApril 16, 2024 | c-span.orgCSinking of TitanicApril 1, 2024 | c-span.orgCSenator Laphonza Butler on Book BansMarch 29, 2024 | c-span.orgCAttention Span TestMarch 25, 2024 | psychologytoday.comPJane MarieMarch 17, 2024 | c-span.orgCThe ShowmanMarch 11, 2024 | c-span.orgCSuper Tuesday Primary ResultsMarch 6, 2024 | c-span.orgCSouth Carolina Republican Primary CoverageFebruary 25, 2024 | c-span.orgCGateway to StatesmanshipFebruary 25, 2024 | c-span.orgCAbout Books with Daniel PaisnerFebruary 23, 2024 | c-span.orgCLectures in History VideosFebruary 19, 2024 | c-span.orgCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRIFF, SOAN, HILS, and MRNS Company DescriptionsHillstream BioPharma NASDAQ:HILS$1.86 +0.04 (+2.20%) As of 07/3/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Nuvo Pharmaceuticals OTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.AngioSoma OTCMKTS:SOANAngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
